HF Advisory Group LLC Raises Stock Holdings in Kenvue Inc. (NYSE:KVUE)

HF Advisory Group LLC lifted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 15.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,205 shares of the company’s stock after acquiring an additional 14,686 shares during the period. Kenvue accounts for about 1.2% of HF Advisory Group LLC’s holdings, making the stock its 21st biggest position. HF Advisory Group LLC’s holdings in Kenvue were worth $2,549,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of KVUE. Yacktman Asset Management LP raised its position in Kenvue by 2.9% in the 3rd quarter. Yacktman Asset Management LP now owns 8,381,404 shares of the company’s stock valued at $193,862,000 after purchasing an additional 232,631 shares during the last quarter. National Pension Service raised its holdings in shares of Kenvue by 14.5% in the third quarter. National Pension Service now owns 2,829,772 shares of the company’s stock valued at $65,453,000 after buying an additional 357,672 shares during the last quarter. Cohen Capital Management Inc. boosted its stake in shares of Kenvue by 1.6% during the third quarter. Cohen Capital Management Inc. now owns 168,193 shares of the company’s stock worth $3,890,000 after buying an additional 2,640 shares during the period. CORDA Investment Management LLC. grew its holdings in shares of Kenvue by 1.3% during the third quarter. CORDA Investment Management LLC. now owns 1,235,630 shares of the company’s stock worth $28,580,000 after buying an additional 16,270 shares during the last quarter. Finally, Allen Wealth Management LLC grew its holdings in shares of Kenvue by 14.4% during the third quarter. Allen Wealth Management LLC now owns 76,558 shares of the company’s stock worth $1,771,000 after buying an additional 9,618 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $23.23 on Wednesday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.57. The company’s 50 day simple moving average is $22.57 and its 200 day simple moving average is $20.47. The company has a market capitalization of $44.48 billion, a price-to-earnings ratio of 40.04, a PEG ratio of 2.97 and a beta of 1.36. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 EPS. On average, sell-side analysts predict that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.53%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s payout ratio is 141.38%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. UBS Group lifted their price objective on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Citigroup reduced their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Bank of America upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Jefferies Financial Group began coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.